Telavancin, originally compound 21, was discovered by Theravance using the company’s multivalent drug design technique in a research programme that aimed to fi nd new antibiotics for serious infections caused by Staphylococcus aureus (including multidrug resistant strains) and other Gram-positive pathogens.